A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHuazhong University of Science and Technology

About this trial

Radiation pneumonitis is the main dose-limiting toxicity of thoracic radiotherapy, which can affect life quality, survival, and the tumor-controlling effects of patients receiving thoracic radiotherapy.

The purpose of this study is to:

* Identify biomarkers including serum proteins, gene expression, genetic changes, and epigenetic modifications that determine radiation pneumonitis. * Investigate the relationship between radiation pneumonitis and other toxicities induced by radiotherapy. * Construct a predictive model for radiation pneumonitis. * Evaluate survival and treatment outcome of patients with radiation pneumonitis.

Eligibility criteria

Qualifiers

Clinical diagnosis of lung cancer by histology

Radiation dose at least 45 Gy

Karnofsky >60

Age>18

Disqualifiers

Previous thoracic irradiation

Severe cardiopulmonary diseases

Trial design

Treatments tested in this trial

  • Blood Samples for Biomarkers

Treatment groups

300 Participants
are divided into 1 treatment group

Locations

3
Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology43000, WuhanHubei, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology430030, WuhanHubei, China
Jingjiang People' Hospital214500, JingjiangJiangsu, China

Sponsors and collaborators

Huazhong University of Science and Technology

Lead sponsor

Hubei Cancer Hospital

Collaborator

Jingjiang People' Hospital

Collaborator